Dr. Slaoui has been serving on the Company’s Board of Directors since June 2024. "Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are ...
Dr. Slaoui has been serving on the Company’s Board of Directors since June 2024. “Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are ...
Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of directors since June 2024. Published first on TheFly ...
SAN DIEGO - Arcturus Therapeutics (NASDAQ:ARCT) Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui ...
SAN DIEGO - Arcturus Therapeutics (NASDAQ:ARCT) Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui as ...
Slaoui is noted for his work with Operation Warp Speed, the COVID-19 vaccine project launched by the Trump administration, where he was scientific head until he stepped down in January.
As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises "substantial doubt" about its ability to continue as a going concern.
Dr. Slaoui has been serving on the Company’s Board of Directors since June 2024. “Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback